Iambic Therapeutics' IPO
Listed Oct 15, 2026 at $16 on Nasdaq as IAM.
Today 9.9% below its $16 offer price; its first day closed +18.2%.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does Iambic Therapeutics do?
“We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry.”
| Fact | Iambic Therapeutics |
|---|---|
| Incorporated | Delaware, 2019 |
| Headquarters | San Diego, California |
| Employees | 171 full-time, as of September 18, 2026 |
| Website | iambic.ai |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | Iambic Therapeutics |
|---|---|
| Shares offered | 9,375,000 |
| Offer price | $16 a share |
| Raised at that price | $150 million |
| Underwriters' discount | $10.5 million |
| Net proceeds the company expects | About $135 million |
| Underwriters' option | 1,406,250 more shares |
| Underwriters | J.P. Morgan, Jefferies, BofA Securities, and Citigroup |
| Exchange | Nasdaq Global Select Market, as IAM |
| Shares outstanding after | 47,400,796 |
| Market cap at the offer price | $758 million |
What the filing says about its money
| Fact | Iambic Therapeutics |
|---|---|
| Collaboration revenue | $9.4 million, year to December 31, 2025 |
| Net loss | $77.3 million, year to December 31, 2025 |
| Cash | $208 million, as of June 30, 2026 |
| Last preferred stock | Series B preferred |
| Raised before the IPO | $537 million in private financings |
What risks does Iambic Therapeutics name first?
- “We have a limited operating history and have incurred significant losses and negative cash flows, and we anticipate that we will continue to incur losses and may never achieve or maintain profitability.”
- “We will require substantial additional capital, which may not be available on acceptable terms, if at all.”
- “Our business depends on establishing and maintaining strategic partnerships, including with AbbVie, Takeda, Lundbeck, and a small number of partners have accounted for a substantial portion of our revenue.”
Every date of Iambic Therapeutics' IPO
| What | Day |
|---|---|
| Registration filed | Sep 21, 2026 |
| Exchange registration filed | Oct 13, 2026 |
| Declared effective by the SEC | Oct 14, 2026 |
| Priced | Oct 14, 2026 |
| First trade | Oct 15, 2026 |
| Lock-up ends | Apr 12, 2027 |
How did its first days trade?
From its daily bars, each close against its $16 offer price.
| Day | Open | Close | From the offer |
|---|---|---|---|
| Oct 15 | $16.15 | $18.91 | +18.2% |
| Oct 16 | $19.31 | $23.81 | +48.8% |
| Oct 19 | $21 | $16.34 | +2.1% |
| Oct 20 | $16.31 | $16.01 | +0.1% |
| Oct 21 | $15.50 | $15.80 | -1.2% |
What is Iambic Therapeutics' Quality Score?
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
Iambic Therapeutics IPO questions
When is Iambic Therapeutics' IPO?
Listed Oct 15, 2026 at $16 on Nasdaq as IAM.
What is Iambic Therapeutics' IPO price?
Iambic Therapeutics' IPO priced at $16 a share, per its final prospectus of Oct 15, 2026.
How many shares is Iambic Therapeutics selling?
9,375,000 shares, and the underwriters may buy 1,406,250 more, per its final prospectus (424B4).
Who are the underwriters?
J.P. Morgan, Jefferies, BofA Securities, and Citigroup, as the prospectus's cover names them.
When does the lock-up end?
Iambic Therapeutics' IPO lock-up ends Apr 12, 2027. Its final prospectus says: “.”
Does Breakaway rate Iambic Therapeutics?
Iambic Therapeutics has a Quality Score of 3 today, marked New listing for its first 21 sessions. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.
Can Breakaway say where Iambic Therapeutics' price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every new listing, ranked live, free. No account.
See all 16 new listings rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.